Osteoporosis

October 20, 2022

E Michael Lewiecki, MD, discusses his CCR West presentation “Sequential Therapy in Osteoporosis: When Does the Order Matter?”

October 20, 2022

E Michael Lewiecki, MD, discusses his CCR West presentation “When is Osteopenia Osteoporosis?”

September 16, 2022

The guidelines will provide more options for the treatment and prevention of glucocorticoid-induced osteoporosis and will inform rheumatologists about the requirements for anti-resorptive therapy after anabolic agents are discontinued.

September 14, 2022

The updated guidelines highlight new recommendations for medications, flexibility in drug selection, and sequential therapy.

October 25, 2021

On this month's episode of Overdrive, E Michael Lewiecki, MD, discusses recent controversies and trends in osteoporosis management, predictions for 2022, and how COVID-19 impacted the treatment landscape for rheumatologists.

October 11, 2021

E Michael Lewiecki, MD, discusses his CCR West presentations entitled, “Controversies in Osteoporosis” and “What's New in Osteoporosis for 2021?”

May 12, 2021

Analysis indicates women with thinning or weakened bones were at an increased risk of atherosclerotic cardiovascular disease events.

February 15, 2021

A study published in Osteoporosis International focused on the changes that have occurred over the course of the pandemic for patients with osteoporosis and found that there have been delays in dual-energy X-ray absorptiometry (DXA) scanning, problems with medication supply, a decrease in face-to-face consultations, and reductions in parenteral medication delivery.

January 22, 2021

“Based on 16,235 pairs of zoledronic acid and denosumab initiators (for osteoporosis), we found a greater risk (HR 1.25, 95% CI 1.04-1.50) of atrial fibrillation with zoledronic acid vs denosumab: an absolute risk difference of 3.69 events per 1000 person-years,” said Seoyoung Kim, MD, ScD.

January 19, 2021

Dr Joan Lo, MD, a research scientist with the Kaiser Permanente Northern California Division of Research, said: “We found that hip fracture risk in women did not differ if women stopped bisphosphonate use after five years or stayed on the medication for 10 years. Whether there is a benefit to staying on the drug for seven years needs to be further studied in randomized trials.”